Righting the copywrong
Amending the Copyright Act to give directors, composers and musicians rights over their work has corrected a historic wrong but trouble is brewing
Getting more with less
System of crop intensification, specially in rice, has shown sizeable savings in water and seed usage. Yet its adoption has not spread despite …
Patent hypocrisies of US
American business lobbies are spreading falsehoods about India’s patent policies—and glossing over their double standards
Drug affordability test
Natco’s bid for a compulsory licence to manufacture a Bayer anti-cancer drug is a test of the law’s ‘reasonable price’ …
Dangers ahead at WTO
The trade facilitation agreement paves the way for fresh pressures on developing countries such as tariff cuts on industrial products
A lethal secrecy in trade deals
Why do democratic governments hide trade negotiations that have dire consequences for public services?
Pursuing a nationalist IPR policy
India has enough laws to protect its intellectual property rights. It is the implementation that is wanting
The pirates come ashore
German Pirate Party’s strong showing in the May elections is a sign that anti-IPR movements resonate with the people
Bringing Google to book
Google’s digital library project went too far, creating a monopoly over the heritage of books
Industry paid for IP seminars to train judges
Microsoft and Indian Music Industry funded FICCI to hold roundtable for Maharashtra judiciary; judges handling piracy cases special invitees
Patent issues delaying Ebola cure
Canada's exclusive licensing rights of its Ebola patent to a US firm are holding up global development of a vaccine
ACTA fury goes viral
Europe is on the boil over an anti-piracy bill that will curb Internet freedom but its impact on trade in generic medicines is not on the radar
Obituary: Ashish Bose, a man who counted
India’s foremost demographer had a lively interest in a host of societal issues, specially the state of the aam aadmi
Big pharma’s dirty tricks
Drug giants from GSK, Abbott and Pfizer to Bayer have been fined for serious malpractices. They should be under close watch in India
New endosulfan ploy
Industry is sidestepping issues by pitching the proposed UN ban on endosulfan as the battle between generics and patented pesticides
Predatory EU pacts
EU is pushing India and Canada to sign free trade agreements that will hurt their generic drugs—and the outrage is global
WTO gives India a clean chit
Apex trade regulator finds nothing amiss in India's intellectual property laws after exhaustive review
The GM maize rats
Findings of the Seralini lab on effect of Monsanto’s GM maize on rats set off a global furore
Biotech industry has a new patron
Department of Biotechnology is playing venture capitalist to private companies to push biotech research in agriculture
Unholy smoke!
Inclusion of intellectual property in bilateral investment agreements is injurious to the health of developing nations
India shakes up WTO
The fracas over India's refusal to meet the deadline on trade facilitation exposes rich nations' double standards
Foreign food invasion
A growing taste for foods from across the globe is adding hugely to India’s import bill for groceries and raising health concerns
Testing the CL route
Roche’s Herceptin will be a test case for government and generics industry as India readies to issue compulsory licences for life-saving drugs
Standing up to the US
India does not have to be apologetic about its patents law, which is fully compliant with WTO requirements on intellectual property protection
EU threat to farmers
Free trade pact with EU will have a severe impact on Indian agriculture, specially the dairy sector